WO1985000968A1 - Procede d'administration de liposomes servant a diminuer la toxicite d'un medicament antitumoral - Google Patents
Procede d'administration de liposomes servant a diminuer la toxicite d'un medicament antitumoral Download PDFInfo
- Publication number
- WO1985000968A1 WO1985000968A1 PCT/US1984/001431 US8401431W WO8500968A1 WO 1985000968 A1 WO1985000968 A1 WO 1985000968A1 US 8401431 W US8401431 W US 8401431W WO 8500968 A1 WO8500968 A1 WO 8500968A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- alpha
- tocopherol
- liposomes
- toxicity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
Definitions
- the method comprises trapping the drug and a drug-protective compound, at a selected ratio, in the same lipid bilayer vesicles.
- the drug-protective compound is one which itself decreases the toxicity of the drug when both compounds are administered in free form.
- the anti-tumor drug is AM
- the drug-protective compound is alpha-tocopherol
- the toxicity of AM when encapsulated in liposomes containing alpha-tocopherol is decreased more than about 60% over that of AM entrapped in vesicles containing no alpha-tocopherol. It is one object of the invention, therefore, to provide a novel method for reducing the toxicity of drugs.
- a more particular object of the invention is to provide a method for reducing the toxicity of an anti-tumor drug, such as AM. by including the drug in liposomes also containing a drug-protective compound, such as alpha-tocopherol.
- Still another object of the invention is to provide such a method which is applicable to a wide range of drugs and drug-protective compounds, both soluble and lipophilic.
- a further object of the invention is to provide a therapeutic agent comprising liposomes containing an entrapped anti-tumor drug, such as AM, and a coentrapped drug-protective compound. 5
- Multilamellar liposomes were made by first mixing 60 ⁇ oles of a 1:4:4 molar ratio mixture of phosphatidylglycerol; phophatidylcholine and cholesterol (in chloroform) with 1.5 mg AM (in methanol) and 0.6
- the therapeutic effects of AM were tested using DBA 2J mice injected intraperitoneally with 10 L1210 leukemia cells.
- the animals were treated one day later by intravenous injection of AM, either in the form of free AM, liposomes entrapping AM only (AM/liposomes). or liposomes entrapping both AM and alpha-tocopherol (AM-aT/liposomes) .
- the dosages of AM administered expressed in milligrams AM per kilogram animal body weight, are given at the left in Table I below.
- the day of death of the animals was recorded, and the mean survival time of each group was calculated. Each group contained from between 6 and 10 mice. The mean survival time and calculated standard deviations are shown at the three columns at the right in Table I.
- AM-aT/liposomes in doses of 2, 5, 10, 15, 20, 25, 30. 50, 75, 100 mg AM per kg animal body weight.
- the data are expressed in terms of LD ⁇ o , i.e., the dosage (in mg drug per kilogram of animal body weight) which produces death in half the animals receiving the drug.
- the upper row in Table II gives the D 5 _ data for mice dying within 14 days after drug administration (acute), the lower row, for mice dying between 50 and 120 days after drug administration (chronic).
- the number of mice available for determination of chronic toxicity (survival of acute toxicity) varied from between about 2 and 10 mice per group.
- Mean LD 5 _ (mg/kg) +.S.D. free AM AM/liposomes AM-aT/liposomes acute 20 +5 45 ⁇ 5 >75 chronic 12 +5 30 +5 50
- drug-protective liposomes described herein had an alpha-tocopherol to total lipid ratio of about 1:100.
- the ratio of alpha-tocopherol to total liposome lipids can be made much greater, preferably in the molar ratio range of 1:20 to 1:5, i.e.. between about 5 and 20 mole percent alpha-tocopherol.
- a preferred therapeutic agent of the invention comprises liposomes containing phospholipid.
- cholesterol, alpha-tocopherol succinate and AM at molar percentages of between about 30% and 70%, 20% and 50%, 5% and 20% and 0.2% and 15%, respectively.
- the data supports the concept of using liposomes to carry more than one agent simultaneously, where one of the agents is a drug and the other agent is either a drug-protective compound, such as disclosed herein, or a drug-potentiating compound which promotes the action of the drug at the site of drug delivery.
- examples of other drug-protective compounds which have been shown to reduce anthracycline cardiac toxicity when administered in free form, include hydroxybutylated toluene, N-acetylcysteine (reference 15) and niacin and isocitrate (reference 16). In practicing the method of the present invention, these compounds would be coentrapped, for example, at encapsulated concentrations of between about 5-100 mg/ml in anthracycline-containing liposomes. to produce an enhanced reduction in drug toxicity.
- Compounds that potentiate anthracycline activity include agents that block calcium uptake, such as verapamil (reference 17). compounds that interfere with calcium mobilization from an intracellular store, such as 8-(N,N-diethylamino)-octyl-3. 4,5-trimethoxy- benzoate (TMB-8) (reference 18), or compounds that interfere with calcium binding to the protein
Abstract
Procédé visant à diminuer la toxicité d'un médicament antitumoral. Le médicament est emprisonné dans des liposomes contenant également un composé protecteur contre les effets secondaires du médicament.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52989083A | 1983-09-06 | 1983-09-06 | |
US529,890 | 1983-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985000968A1 true WO1985000968A1 (fr) | 1985-03-14 |
Family
ID=24111649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1984/001431 WO1985000968A1 (fr) | 1983-09-06 | 1984-09-06 | Procede d'administration de liposomes servant a diminuer la toxicite d'un medicament antitumoral |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0153955A1 (fr) |
WO (1) | WO1985000968A1 (fr) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756910A (en) * | 1985-11-29 | 1988-07-12 | Kabushiki Kaisha Vitamin Kenkyusyo | Adriamycin-entrapping liposome preparation |
US4769250A (en) * | 1985-10-15 | 1988-09-06 | Vestar, Inc. | Antracycline antineoplastic agents encapsulated in phospholipid vesicle particles and methods for using same for tumor therapy |
US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
US4923854A (en) * | 1986-01-22 | 1990-05-08 | The Liposome Company, Inc. | Solubilization of hydrophobic materials using lysophospholipid |
US4946683A (en) * | 1987-11-18 | 1990-08-07 | Vestar, Inc. | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes |
US4981690A (en) * | 1987-10-27 | 1991-01-01 | Board Of Regents, The University Of Texas System | Liposome-incorporated mepartricin |
US5041278A (en) * | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
EP0464135A1 (fr) * | 1989-03-13 | 1992-01-08 | Kenneth Naoyuki Matsumura | Procede de reduction des effets secondaires d'un medicament. |
US5082664A (en) * | 1987-05-22 | 1992-01-21 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
US5132290A (en) * | 1988-01-19 | 1992-07-21 | The Board Of Regents, The University Of Texas System | Esters of 3'-deaminodoxorubicin and liposomal compositions thereof |
US5204112A (en) * | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5262168A (en) * | 1987-05-22 | 1993-11-16 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
US5364631A (en) * | 1987-10-19 | 1994-11-15 | The Liposome Company, Inc. | Tocopherol-based pharmaceutical systems |
EP0655239A1 (fr) * | 1993-11-25 | 1995-05-31 | Lipotec, S.A. | Liposomes encapsulant de la doxorubicine |
US5556580A (en) * | 1987-04-16 | 1996-09-17 | The Liposome Company, Inc. | Liposome continuous size reduction method and apparatus |
US5614214A (en) * | 1993-05-21 | 1997-03-25 | The Liposome Company, Inc. | Reduction of liposome-induced adverse physiological reactions |
US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
US5616341A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | High drug:lipid formulations of liposomal antineoplastic agents |
WO1999027908A1 (fr) * | 1997-12-04 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Traitement chimio et immunotherapeutique combine a l'aide de medicaments et de cytokines encapsules dans des liposomes |
US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
EP1435231A1 (fr) * | 2002-12-31 | 2004-07-07 | Bharat Serums & Vaccines Ltd. | Liposomes non-pegylés à longue durée de circulation |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US7153490B2 (en) | 2000-10-10 | 2006-12-26 | Lipotec, Sa | Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9402845B2 (en) | 2005-12-08 | 2016-08-02 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US9566234B2 (en) | 2012-05-21 | 2017-02-14 | Insmed Incorporated | Systems for treating pulmonary infections |
US9827317B2 (en) | 2002-10-29 | 2017-11-28 | Insmed Incorporated | Sustained release of antiinfectives |
US9895385B2 (en) | 2014-05-15 | 2018-02-20 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US9925205B2 (en) | 2007-05-04 | 2018-03-27 | Insmed Incorporated | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof |
US10124066B2 (en) | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
US10363226B2 (en) | 2015-08-12 | 2019-07-30 | North Carolina State University | Platelet membrane-coated drug delivery system |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
US11571386B2 (en) | 2018-03-30 | 2023-02-07 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
US4241046A (en) * | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4256632A (en) * | 1978-08-24 | 1981-03-17 | Yeda Research And Development Co. Ltd. | Novel derivatives of daunomycin |
US4263428A (en) * | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4419348A (en) * | 1981-04-27 | 1983-12-06 | Georgetown University | Anthracycline glycoside compositions, their use and preparation |
-
1984
- 1984-09-06 EP EP19840903412 patent/EP0153955A1/fr not_active Withdrawn
- 1984-09-06 WO PCT/US1984/001431 patent/WO1985000968A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
US4263428A (en) * | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4256632A (en) * | 1978-08-24 | 1981-03-17 | Yeda Research And Development Co. Ltd. | Novel derivatives of daunomycin |
US4241046A (en) * | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4419348A (en) * | 1981-04-27 | 1983-12-06 | Georgetown University | Anthracycline glycoside compositions, their use and preparation |
Non-Patent Citations (14)
Title |
---|
DIPLOCK, A.T., LUCY, J.A., VERRIRDER, M. and ZIELINIEWSKI, A. Alpha-Tocopherol and the Permeability to Glucose and Chromate of Unsaturated Liposomes. Febs. Lett. * |
FORSSEN E.A. and TOKES, Z. A. Use of Anionic Liposomes for the Reduction of Chronic Doxorubicin Induced Cardiotoxicity. Proc. Nat. Acad. Sci. USA 78:1873-1877 (1981) * |
FORSSEN, E.A. and TOKES, Z. A. In Vitro and in Vivo Studies with Adriamycin Liposomes. Biochem. Biophys. Res. Comm. 91:1295-1301 (1979) * |
FUKAZAWA, K., IKENO, H., TOKUMURA, A., and TSUKATANI, H. Effect of alpha-Tocopherol Incoproration on Glucose Permeability and phase Transition of Lecithin Liposomes. Chem. Phys. Lip. 23:13-22 (1979) * |
HUNT, C.A. and TSANG, S. alpha-Tocopherol Retards Auto-Oxidation and Prolongs the shelf life of Liposomes. Int. J. Pharmaceutics 8:101-110 (1981) * |
KONIGS, A.W.T., DARREN, J. and TRIELING, Protection of Liposomal Lipids against Radiation Induced Oxidative Damage. Int. J. Radiat. Biol. 35:343-350 (1979) * |
MASLOW, D. E., MAYHEW, E., OLSON, F., and Rustum, Y. Reduction of the Inhibitory effect of Adriamycin on Myocardial Contraction in Virto by Entrapment in Liposomes. Proc. Am. Assoc. Cancer Res. 21:281 (1980) * |
MAYHEW, E. and RUSTUM, Y.M. Effect of Liposome Entrapped Adriamycin (AM) against Ovarian Tumor M5076 "Metastatic" to the Liver. Proc. Am. Assoc. Cancer Res. 23:170 (Astract #668) (March 1982) * |
MAYHEW, E., RUSTUM, Y.M., SZOKA, F. and PAPAHADJOPOULOS, D. ROLE of Cholesterol in Enhancing the anti-Tumor Activity of l-alpha-D-Arabinofuranosylcytosine Entrapped in Reverse phase Evaporation Vesicles. Cancer Treatment Reports 63:1923-1928 (1979) * |
MYERS, E., McGUIRE, W. and Young, R. Adriamycin Amelioration of Toxicity by alpha-Tocopherol. Cancer Treatment Reports 60:961-962 (1976) * |
OLSON, F., MAYHEW, E., MASLOW, D., RUSTUM, Y. and SZOKA, F. Characterization, Toxicity and Therapeutic Efficacy of Adriamycin Encapsulated in Liposomes. Eur. J. Cancer (in press) * |
RAHMAN, A., KESSLER, A., MORE, N., SIKIE, B., ROWDEN, G., WOOLLEY, P. and SCHEIN, P.S. Liposomal Protection of Adriamycin-Induced Cardiotoxicity in Mice. Cancer Res. 40: 1532-1537 (1980) * |
SONNEVELD, P. Effect of alpha-Tocopherol on the Cardiotoxicity of Adriamycin in the Rat. Cancer Treatment Reports 62:1033-1036 (1978) * |
WANG, Y.M., MADANAT, F.F., KIMBALL, J.C., GLEISER, C.A., ALI, M.K., KAUFMAN, M.Q. and van Eyes, J. Effect of Vitamin E against Adriamycin-Indiced Toxicity in Rabbits. Cancer Res. 49:1022-1027 (1980) * |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5330689A (en) * | 1985-10-15 | 1994-07-19 | The Liposome Company, Inc. | Entrapment of water-insoluble compound in alpha tocopherol-based vesicles |
US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
US4769250A (en) * | 1985-10-15 | 1988-09-06 | Vestar, Inc. | Antracycline antineoplastic agents encapsulated in phospholipid vesicle particles and methods for using same for tumor therapy |
US5041278A (en) * | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
EP0460720A2 (fr) * | 1985-10-15 | 1991-12-11 | The Liposome Company, Inc. | Procédé pour extruder des liposomes |
EP0460720A3 (en) * | 1985-10-15 | 1992-01-02 | The Liposome Company, Inc. | A method of extruding liposomes |
US5234634A (en) * | 1985-10-15 | 1993-08-10 | The Liposome Company, Inc. | Method for preparing alpha-tocopherol vesicles |
US4756910A (en) * | 1985-11-29 | 1988-07-12 | Kabushiki Kaisha Vitamin Kenkyusyo | Adriamycin-entrapping liposome preparation |
US4923854A (en) * | 1986-01-22 | 1990-05-08 | The Liposome Company, Inc. | Solubilization of hydrophobic materials using lysophospholipid |
US5204112A (en) * | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5376452A (en) * | 1986-06-16 | 1994-12-27 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5616341A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | High drug:lipid formulations of liposomal antineoplastic agents |
US5795589A (en) * | 1987-03-05 | 1998-08-18 | The Liposome Company, Inc. | Liposomal antineoplastic agent compositions |
US6083530A (en) * | 1987-03-05 | 2000-07-04 | The Liposome Company, Inc. | High drug:lipid formulations of liposomal-antineoplastic agents |
US5744158A (en) * | 1987-03-05 | 1998-04-28 | The Liposome Company, Inc. | Methods of treatment using high drug-lipid formulations of liposomal-antineoplastic agents |
US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
US5556580A (en) * | 1987-04-16 | 1996-09-17 | The Liposome Company, Inc. | Liposome continuous size reduction method and apparatus |
US5262168A (en) * | 1987-05-22 | 1993-11-16 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
US5082664A (en) * | 1987-05-22 | 1992-01-21 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
US5364631A (en) * | 1987-10-19 | 1994-11-15 | The Liposome Company, Inc. | Tocopherol-based pharmaceutical systems |
US4981690A (en) * | 1987-10-27 | 1991-01-01 | Board Of Regents, The University Of Texas System | Liposome-incorporated mepartricin |
US4946683A (en) * | 1987-11-18 | 1990-08-07 | Vestar, Inc. | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes |
US5132290A (en) * | 1988-01-19 | 1992-07-21 | The Board Of Regents, The University Of Texas System | Esters of 3'-deaminodoxorubicin and liposomal compositions thereof |
US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
EP0464135A1 (fr) * | 1989-03-13 | 1992-01-08 | Kenneth Naoyuki Matsumura | Procede de reduction des effets secondaires d'un medicament. |
EP0464135A4 (en) * | 1989-03-13 | 1992-04-01 | Kenneth Naoyuki Matsumura | Method for reducing side effects of a drug |
US5614214A (en) * | 1993-05-21 | 1997-03-25 | The Liposome Company, Inc. | Reduction of liposome-induced adverse physiological reactions |
US5662930A (en) * | 1993-05-21 | 1997-09-02 | The Liposome Company, Inc. | Reduction of liposome-induced adverse physiological reactions |
WO1995014459A1 (fr) * | 1993-11-25 | 1995-06-01 | Lipotec, S.A. | Liposomes d'encapsulation de la doxorubicine |
EP0655239A1 (fr) * | 1993-11-25 | 1995-05-31 | Lipotec, S.A. | Liposomes encapsulant de la doxorubicine |
ES2072223A1 (es) * | 1993-11-25 | 1995-07-01 | Lipotec Sa | Liposomas encapsulando doxorubicina. |
US5605703A (en) * | 1993-11-25 | 1997-02-25 | Lipotec, S.A. | Liposomes encapsulating doxorubicin |
WO1999027908A1 (fr) * | 1997-12-04 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Traitement chimio et immunotherapeutique combine a l'aide de medicaments et de cytokines encapsules dans des liposomes |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US7153490B2 (en) | 2000-10-10 | 2006-12-26 | Lipotec, Sa | Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors |
US9827317B2 (en) | 2002-10-29 | 2017-11-28 | Insmed Incorporated | Sustained release of antiinfectives |
EP1435231A1 (fr) * | 2002-12-31 | 2004-07-07 | Bharat Serums & Vaccines Ltd. | Liposomes non-pegylés à longue durée de circulation |
AU2003303368B2 (en) * | 2002-12-31 | 2010-06-17 | Zydus Bsv Pharma Private Limited | Non-pegylated long-circulating liposomes |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US9402845B2 (en) | 2005-12-08 | 2016-08-02 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US10328071B2 (en) | 2005-12-08 | 2019-06-25 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
EP3718532A1 (fr) | 2005-12-08 | 2020-10-07 | Insmed Incorporated | Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires |
EP3067046A1 (fr) | 2005-12-08 | 2016-09-14 | Insmed Incorporated | Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires |
EP3067047A1 (fr) | 2005-12-08 | 2016-09-14 | Insmed Incorporated | Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires |
US9511082B2 (en) | 2005-12-08 | 2016-12-06 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US9549925B2 (en) | 2005-12-08 | 2017-01-24 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US9549939B2 (en) | 2005-12-08 | 2017-01-24 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US9925205B2 (en) | 2007-05-04 | 2018-03-27 | Insmed Incorporated | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof |
US10064882B2 (en) | 2007-05-07 | 2018-09-04 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9724301B2 (en) | 2007-05-07 | 2017-08-08 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9737555B2 (en) | 2007-05-07 | 2017-08-22 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
EP4331675A2 (fr) | 2012-05-21 | 2024-03-06 | Insmed Incorporated | Systèmes de traitement d'infections pulmonaires |
US9566234B2 (en) | 2012-05-21 | 2017-02-14 | Insmed Incorporated | Systems for treating pulmonary infections |
EP4005576A1 (fr) | 2012-05-21 | 2022-06-01 | Insmed Incorporated | Systèmes de traitement d'infections pulmonaires |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
US10471149B2 (en) | 2012-11-29 | 2019-11-12 | Insmed Incorporated | Stabilized vancomycin formulations |
US10124066B2 (en) | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
US10588918B2 (en) | 2014-05-15 | 2020-03-17 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US10238675B2 (en) | 2014-05-15 | 2019-03-26 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US9895385B2 (en) | 2014-05-15 | 2018-02-20 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US10751355B2 (en) | 2014-05-15 | 2020-08-25 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US10251900B2 (en) | 2014-05-15 | 2019-04-09 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US10828314B2 (en) | 2014-05-15 | 2020-11-10 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
EP3766501A1 (fr) | 2014-05-15 | 2021-01-20 | Insmed Incorporated | Méthodes de traitement d'infections pulmonaires mycobactériennes non-tuberculeuses |
EP3466432A1 (fr) | 2014-05-15 | 2019-04-10 | Insmed Incorporated | Méthodes de traitement d'infections pulmonaires mycobactériennes non-tuberculeuses |
US10398719B2 (en) | 2014-05-15 | 2019-09-03 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US11395830B2 (en) | 2014-05-15 | 2022-07-26 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
US11446318B2 (en) | 2014-05-15 | 2022-09-20 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
EP4122470A1 (fr) | 2014-05-15 | 2023-01-25 | Insmed Incorporated | Méthodes de traitement d'infections pulmonaires mycobactériennes non-tuberculeuses |
US10363226B2 (en) | 2015-08-12 | 2019-07-30 | North Carolina State University | Platelet membrane-coated drug delivery system |
US11571386B2 (en) | 2018-03-30 | 2023-02-07 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
Also Published As
Publication number | Publication date |
---|---|
EP0153955A1 (fr) | 1985-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1985000968A1 (fr) | Procede d'administration de liposomes servant a diminuer la toxicite d'un medicament antitumoral | |
US4873088A (en) | Liposome drug delivery method and composition | |
Cortesi et al. | Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion | |
Mayhew et al. | Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid | |
CA1338702C (fr) | Formulations d'agents liposomiques-antineoplasiques a faible teneur en medicaments-lipides | |
US4769250A (en) | Antracycline antineoplastic agents encapsulated in phospholipid vesicle particles and methods for using same for tumor therapy | |
Rubas et al. | Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes | |
US5814335A (en) | Sphingosomes for enhanced drug delivery | |
US5178876A (en) | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes | |
US6146659A (en) | Method of administering liposomal encapsulated taxane | |
Gabizon et al. | Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model | |
Harrington et al. | Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development | |
US4863739A (en) | Liposome compositions of anthracycline derivatives | |
EP0721328A1 (fr) | Compositions de camptothecine | |
Boman et al. | Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy | |
US7029696B2 (en) | Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes | |
WO1995014459A1 (fr) | Liposomes d'encapsulation de la doxorubicine | |
Chang et al. | Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice | |
Lopez-Berestein et al. | Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine | |
Perez-Soler et al. | Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1, 2-diaminocyclohexane platinum (II) encapsulated in multilamellar vesicles | |
CA2508166A1 (fr) | Compositions et methodes associees aux formulations de lipide:emodine | |
Schwendener et al. | Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy | |
HOSODA et al. | Antitumor activity of doxorubicin encapsulated in poly (ethylene glycol)-coated liposomes | |
Sur et al. | Effect of liposomal encapsulation of cis-platinum diamminodichloride in the treatment of Ehrlich ascites carcinoma | |
DOI et al. | Therapeutic effect of reticuloendothelial system (RES)-avoiding liposomes containing a phospholipid analogue of 5-fluorouracil, dipalmitoylphosphatidylfluorouridine, in Meth A sarcoma-bearing mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): JP |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB LU NL SE |